Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Guaranteeing Quality Medical care with Federal medical care Benefit Plans. - 23 astronauts settle into their new life in orbit | On the International Space Station this week Dec. 1-5, 2025
- 3The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- 410 times the sky amazed us in 2025
- 5Vote In favor of Your Favored Comupter Game
- Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
- Inconceivable Spots To Stargaze All over The Planet
- Vote In favor of Your Number one Savvy Beds
- A hunger for new experiences Narratives: Motivating Travel and Experience
- New dietary guidelines recommend more dairy, meat and fats: What to know
- Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- Best Amusement Park in Asia: Which One Is a Must-Visit
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
